首頁 > 市場調查報告書 > 製藥

疫苗動物用醫藥

市場調查報告書

商品編碼

1285061

全球動物疫苗市場 - 2023-2030年

Global Animal Vaccine Market - 2023-2030

出版日期: 2023年06月05日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球動物疫苗市場在2022年達到120.892億美元，預計到2030年將出現有利可圖的成長，達到224.043億美元。在預測期內（2023-2030），全球動物疫苗市場預計將呈現8.2%的複合成長率。

疫苗接種對於保護動物健康和福祉至關重要。長期以來，它已被證明是降低農場和家庭動物疾病負擔的有效方法。動物健康和疾病預防計劃繼續擴大依賴於疫苗接種。

全球動物疫苗市場正在擴大，因為包括不斷增加的研究和開發及其即將在各國獲得的醫療批准等因素，也為動物疫苗市場的成長創造了一個積極的前景。越來越多的動物採用和新型疫苗的臨床試驗不斷增加，也推動了動物疫苗市場的需求趨勢。

市場動態

不斷成長的研究和開發推動了動物疫苗市場的成長

在動物疫苗領域正在進行各種新穎的研究和開發。研究人員在歐盟的資助下創造的新牲畜疫苗有可能最大限度地減少抗生素耐藥性，提高動物福利，節省資金，並減少對危害環境的化學品的需求。歐盟資助的SAPHIR項目努力通過創造新鮮、有效的疫苗來解決動物疾病預防方面的差距。

研究人員重點關注那些造成重大經濟損失和對抗生素治療有強烈需求的疾病。來自SAPHIR的研究人員利用最新的基因組學和生物統計學方法，確定了建立包含對疫苗高反應的育種技術的生物標記。

此外，他們還使用數學建模技術來預測疫苗在實踐中的效果如何。他們利用尖端技術創造了候選疫苗，可以對最近發現的疾病菌株提供廣泛的免疫力。該團隊在項目結束時已經為影響豬、雞和牛的六種重要牲畜傳染病生產了動物疫苗候選物。因此，不斷成長的研究正在推動動物疫苗的市場規模。

政府計劃的增加和新產品的推出為製造商創造了有利可圖的機會

由於不斷進步和監管部門的批准，以及傳染病的日益流行，動物疫苗市場機會越來越多。主要的關鍵參與者推出的新產品不斷增加，也推動了市場的發展。

許多政府和非政府組織都採取了行動，如歐盟-日本-美國三邊計劃的《獸藥註冊技術標準協調國際合作》（VICH），其目的是協調獸藥產品註冊的技術規範。

VICH的責任是規範獸藥產品上市許可所需資訊的技術標準。這是通過為行銷許可申請中必須包含的研究制定統一的標準來實現的。

動物健康意識的缺乏將阻礙市場的發展

動物健康是至關重要的，因為不健康的動物會產生廣泛的負面效應。此外，影響人類的動物疾病會對其他經濟部門產生影響，如全球貿易、農業穩定和公共衛生。因此，上述因素將在預測期內限制動物健康市場的成長。

COVID-19影響分析

世界上許多國家的COVID-19大流行和封鎖，影響了所有行業的公司的財務健康。因此，在COVID-19公共衛生緊急情況期間，美國食品和藥物管理局（FDA）發布了指導方針，其中包括幫助贊助商和研究人員的一般考慮，確保試驗參與者的安全，堅持良好的臨床實踐（GCP），並儘量減少對動物試驗完整性的風險。

俄烏戰爭影響分析

俄羅斯-烏克蘭衝突估計對全球動物疫苗市場的影響不大，因為該地區的主要市場參與者數量較少。然而，在預測期內，原料進出口的影響預計對全球動物疫苗市場的成長影響不大。

Market Overview

The global animal vaccine market reached US$ 12,089.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 22,404.3 million by 2030. The global animal vaccine market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

Vaccination is vital in preserving animal health and well-being. It has long been proven to be an effective method of lowering disease burden in farm and domestic animals. Animal health and illness prevention programs continue to depend more and more on vaccinations.

The global market for animal vaccines is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the animal vaccine market growth. The increasing adoption of animals and the growing clinical trials for novel vaccines are also driving up demand for animal vaccine market trends.

Market Dynamics

The Rising Research and Development Drive the Growth of the Animal Vaccine Market

Various novel research and developments are being done in the field of animal vaccines. New livestock vaccinations created by researchers with funding from the EU have the potential to minimize antibiotic resistance, increase animal welfare, save money, and lessen the need for chemicals that harm the environment. The EU-funded SAPHIR project made an effort to address the gaps in animal illness prevention by creating fresh, potent vaccinations.

The researchers focused on conditions that cause significant economic losses and a strong demand for antibiotic treatments. Researchers from SAPHIR have identified biomarkers for establishing breeding techniques that incorporate high response to vaccines using the most recent genomic and biostatistical approaches.

In addition, they have used mathematical modeling techniques to forecast how well vaccines will work in practice. They have created vaccination candidates using cutting-edge technologies that can offer wide immunity against recently discovered disease strains. The team has produced animal vaccine candidates for six important livestock infections that impact pigs, chickens, and cattle at the project's conclusion. Hence, the growing research is driving the animal vaccine market size.

Rising Government Initiatives and Novel Product Launches Creates Lucrative Opportunities for Manufacturers

There is a growing animal vaccine market opportunity owing to rising advancements and regulatory approvals and the increasing prevalence of infectious diseases. The rising novel product launches by major key players is also driving the market.

Actions are taken by numerous governmental and non-governmental organizations, such as the trilateral European Union-Japan-US program International Cooperation on Harmonization of Technical Standards for Registration of Veterinary Medicinal Products (VICH), which aims to harmonize the technical specifications for veterinary product registration.

VICH's responsibility is to standardize the technical standards for the information required for a veterinary medical product's marketing authorization. This is accomplished by creating unified standards for the research that must be included in a marketing permission application.

A Lack of Animal Health Awareness will Hamper the Growth of the Market

Animal health is crucial because unhealthy animals can have a wide range of negative effects. Additionally, animal diseases that affect humans can have an effect on other economic sectors such as global trade, agricultural stability, and public health. Hence, the above-mentioned factors will be limiting the animal health market growth over the forecast period.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity for animals.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global animal vaccine market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global animal vaccine market growth over the forecast period.

Segment Analysis

The global animal vaccine market is segmented based on product type, animal type, route of administration and region.

Inactivated Vaccines From Product Type Segment Account for 40.3% of the Market Share Owing to Rising Novel Product Launches

In 2022, the inactivated vaccines segment held a dominant position in the global animal vaccine market. The segment is advantageous because inactivated vaccinations, also known as killed vaccines, are made by killing a pathogen that has been grown and then turned into a vaccine. These vaccines are often used to protect against a variety of bacterial and viral illnesses.

Furthermore, inactivated vaccines elicit powerful immune responses by retaining the inactive genetic element, and the virus surface antigens are essential for a powerful immunological response. Additionally, inactivated immunization is safe and has a higher demand because it doesn't remain in the surroundings or in the fish who have received it.

As a result, there is now a greater need for inactivated aquaculture vaccinations. The market segment is predicted to have the greatest market share during the projection period based on the aforementioned assertions.

Geographical Analysis

North America Accounted For Approximately 39.8% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for animal vaccines for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of animal vaccines, which has increased the demand. North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for animal vaccines.

Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals, and novel product launches. Researchers are becoming more aware of various kinds of treatment or prevention approaches for infectious disorders, leading to the expansion of the market in this region. These factors shows the dominance of North America.

Competitive Landscape

The major global players in the animal vaccine market include: Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Services LLC, Ceva, Vetoquinol, Elanco, Veterquimica S.A., Phibro Animal Health Corporation, KBNP, Inc. and Kyoto Biken Laboratories, Inc. among others.

Why Purchase the Report?

To visualize the global animal vaccine market segmentation based on product type, animal type, route of administration and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of animal vaccine market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global animal vaccine market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Animal Type
3.3. Snippet by Route of Administration
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The Increasing Innovation in Animal Vaccine Production
  - 4.1.1.2. The Rising Research and Development
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Animal Health Awareness
- 4.1.3. Opportunity
  - 4.1.3.1. Rising Regulatory Approvals and Novel Product Launches
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Modified-live (attenuated) Vaccine *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Inactivated (killed) Vaccine
7.4. Recombinant Vaccine
7.5. Toxoid Vaccine

8. By Animal Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 8.1.2. Market Attractiveness Index, By Animal Type
8.2. Companion Animal *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.2.3. Feline
- 8.2.4. Canine
- 8.2.5. Others
8.3. Livestock Animal
- 8.3.1. Poultry
- 8.3.2. Swine
- 8.3.3. Cattle
- 8.3.4. Others
8.4. Aquaculture

9. By Route of Administration

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Subcutaneous *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Intramuscular
9.4. Intranasal

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Merck & Co., Inc. *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Boehringer Ingelheim International GmbH
12.3. Zoetis Services LLC
12.4. Ceva
12.5. Vetoquinol
12.6. Elanco
12.7. Veterquimica S.A.
12.8. Phibro Animal Health Corporation
12.9. KBNP, Inc.
12.10. Kyoto Biken Laboratories, Inc.

LIST NOT EXHAUSTIVE